Biogen
BIIB
1,104 hedge funds and large institutions have $43.5B invested in Biogen in 2021 Q2 according to their latest regulatory filings, with 136 funds opening new positions, 324 increasing their positions, 468 reducing their positions, and 110 closing their positions.
108% more funds holding in top 10
Funds holding in top 10: 13 → 27 (+14)
24% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 110
22% more capital invested
Capital invested by funds: $35.7B → $43.5B (+$7.81B)
1% more funds holding
Funds holding: 1,093 → 1,104 (+11)
0.17% less ownership
Funds ownership: 83.93% → 83.76% (-0.17%)
6% less call options, than puts
Call options by funds: $1.8B | Put options by funds: $1.91B
31% less repeat investments, than reductions
Existing positions increased: 324 | Existing positions reduced: 468
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$445M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$148M |
| 3 |
SC
Samlyn Capital
New York
|
+$114M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$101M |
| 5 |
HM
HealthCor Management
New York
|
+$78.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$184M |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$180M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$171M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$169M |
| 5 |
SAM
Southeastern Asset Management
Memphis,
Tennessee
|
-$169M |
BIIB Hedge Fund Activity: Q2 2021 in Review
1,104 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2021, worth a combined $43.5B — up 22% from $35.7B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new BIIB positions and 110 closed out — a net gain of 26 holders — while 324 added to existing stakes and 468 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $445M. The largest seller was Renaissance Technologies, cutting an estimated $184M.
- 1,104 institutional investors held Biogen (BIIB) as of Q2 2021, up from 1,093 in Q1 2021.
- Funds reported $43.5B of Biogen stock for Q2 2021, up 22% quarter-over-quarter.
- 136 funds opened new Biogen positions in Q2 2021 and 110 closed out, a net change of +26 holders.
- The largest Biogen buyer in Q2 2021 was JP Morgan Chase, an estimated $445M added.
- The largest Biogen seller in Q2 2021 was Renaissance Technologies, an estimated $184M sold.
Based on aggregated 13F filings for Q2 2021.